Cost-minimization analysis of individually tailored or fixed-scheduled rituximab maintenance therapy for antineutrophil-cytoplasm antibody associated vasculitides
Objective: Patients included in MAINRITSAN2 trial received either an individually tailored or a fixed-schedule therapy with rituximab as maintenance treatment of antineutrophil cytoplasm antibody associated vasculitides. The aim of this study was to compare the real-world costs of both arms. Meth...
Saved in:
| Main Authors: | Ana Belén Guisado-Gil, Marina Muñoz-Burgos, Ana Ortega-Eslava, Francisco Javier García-Hernández, Bernardo Santos-Ramos |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-03-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/11287.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rituximab in relapsed/refractory antineutrophil cytoplasmic antibody associated vasculitis: A single-center prospective observational study
by: Ekbote Gayatri, et al.
Published: (2019-01-01) -
Clinical profile and outcome of antineutrophil cytoplasmic antibody-associated vasculitis: A retrospective observational study from South India
by: Sham Santhanam, et al.
Published: (2022-01-01) -
Anti-neutrophil cytoplasmic autoantibodies associated vasculitis – Clinical profile and outcomes
by: Kavya Devi Nunna, et al.
Published: (2018-01-01) -
Clinical value of antineutrophil cytoplasmic antibody positive expression in children with lupus nephritis
by: Jing Wang, et al.
Published: (2024-11-01) -
Antineutrophil cytoplasmic antibody-associated vasculitis in a patient with diffuse scleroderma
by: B N Shiva Prasad, et al.
Published: (2021-01-01)